Description
Thymogen is the defined synthetic form of the EW dipeptide — glutamyl-tryptophan — isolated from Thymalin via reversed-phase HPLC and subsequently synthesized as a precisely characterized molecular entity. Where Thymalin is a complex extract, Thymogen is a single sequence with a known molecular formula, confirmed mass, and reproducible chemical identity across production lots. It is the smallest thymus-derived compound in this catalog, with only two amino acids. Its DNA binding sequence has been identified through molecular docking as GGAG — a specific interaction that positions it in specialty research peptide immune gene regulation research as a tool for probing how minimal peptide sequences encode tissue-specific regulatory information.
Key Characteristics
- Defined single-sequence alternative to Thymalin’s complex — Thymogen provides chemical homogeneity and batch-to-batch reproducibility that the polypeptide complex cannot guarantee, making it the appropriate choice for mechanistic research requiring precise dosing and sequence-specific analysis
- GGAG DNA binding sequence identified by molecular docking — this sequence specificity in the gene promoter region provides molecular-level evidence for how a two-amino-acid peptide achieves tissue-targeted gene regulation, a mechanistic question that is central to the Khavinson bioregulator research framework
- cAMP/cGMP balance modulation has been documented alongside immune gene expression effects — this cyclic nucleotide signaling angle is specific to Thymogen and doesn’t appear in Vilon research, distinguishing the two thymic dipeptides mechanistically despite their shared origin
- ACE2 expression interaction has been studied — Thymogen’s EW sequence reduces angiotensin-induced vasoconstriction and preserves endothelium-dependent vascular relaxation through ACE2 modulation, connecting thymic immune biology to vascular endothelial function research
- Unlike Vilon (KE), which activates T-helper populations primarily through anti-apoptotic mechanisms in aging immune tissue, Thymogen’s primary immune research focus is on T-cell maturation and differentiation in thymic cell models — same target organ, different downstream biology
Handling and Storage
Store as lyophilized powder under refrigeration, away from heat, moisture, and light. As a dipeptide, Thymogen is susceptible to proteolytic degradation. Reconstitute immediately before use and avoid repeated freeze-thaw cycles.
FAQs
What is Thymogen?
Thymogen (EW) is the synthetic dipeptide glutamyl-tryptophan, isolated from the Thymalin polypeptide complex and synthesized as a defined molecular entity. It is studied for immune gene regulation through direct DNA binding at the GGAG sequence, T-cell maturation in thymic cell models, and cAMP/cGMP balance modulation. Its precise chemical identity makes it the appropriate tool when mechanistic thymic research requires a single defined sequence rather than a complex extract.
How does Thymogen relate to Thymalin?
Thymogen is the defined synthetic form of Thymalin’s primary active component. Thymalin is a polypeptide complex containing multiple bioactive sequences, including EW and KE. Thymogen isolates the EW sequence as a single compound, providing chemical homogeneity and allowing researchers to attribute observed effects specifically to the EW sequence rather than to the full complement of bioactive peptides present in Thymalin.
What makes the GGAG DNA binding specificity significant?
GGAG is the specific double-stranded DNA sequence that molecular docking studies identify as the preferential binding site for the EW dipeptide. This sequence specificity supports the Khavinson hypothesis that short bioregulatory peptides achieve tissue-specific gene regulation through direct promoter region binding rather than through non-specific charge-based interactions. For researchers studying the molecular basis of peptide-DNA interaction, this defined binding sequence makes Thymogen a tractable model compound.
